Cognitive behavioral therapy and fluoxetine as adjuncts to group behavioral therapy for binge eating disorder. 2005

Michael J Devlin, and Juli A Goldfein, and Eva Petkova, and Huiping Jiang, and Pamela S Raizman, and Sara Wolk, and Laurel Mayer, and Janel Carino, and Dara Bellace, and Claudia Kamenetz, and Ilyse Dobrow, and B Timothy Walsh
New York State Psychiatric Institute, Unit 116, 1051 Riverside Drive, New York, NY 10032, USA. mjd5@columbia.edu

OBJECTIVE Although binge eating disorder is a common and distressing concomitant of obesity, it has not yet been established whether affected individuals presenting to behavioral weight control programs should receive specialized treatments to supplement standard treatment. This study was designed to examine the added benefit of two adjunctive interventions, individual cognitive behavioral therapy (CBT) and fluoxetine, offered in the context of group behavioral weight control treatment. METHODS One hundred sixteen overweight/obese women and men with binge eating disorder were all assigned to receive a 16-session group behavioral weight control treatment over 20 weeks. Simultaneously, subjects were randomly assigned to receive CBT+fluoxetine, CBT+placebo, fluoxetine, or placebo in a two-by-two factorial design. Outcome measures, assessed at the end of the 16-session acute treatment phase, included binge frequency, weight, and measures of eating-related and general psychopathology. RESULTS Overall, subjects showed substantial improvement in binge eating and both general and eating-related psychopathology, but little weight loss. Subjects who received individual CBT improved more in binge frequency than did those not receiving CBT (p<0.001), and binge abstinence was significantly more common in subjects receiving CBT vs. those who did not (62% vs. 33%, p<0.001). Fluoxetine treatment was associated with greater reduction in depressive symptoms (p<0.05). The 54 subjects who achieved binge abstinence improved more on all measures than the 62 subjects who did not. In particular, these subjects lost, on average, 6.2 kg compared with a gain of 0.7 kg among non-abstainers. CONCLUSIONS Adjunctive individual CBT results in significant additional binge reduction in obese binge eaters receiving standard behavioral weight control treatment.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010349 Patient Compliance Voluntary cooperation of the patient in following a prescribed regimen. Client Adherence,Client Compliance,Non-Adherent Patient,Patient Adherence,Patient Cooperation,Patient Noncompliance,Patient Non-Adherence,Patient Non-Compliance,Patient Nonadherence,Therapeutic Compliance,Treatment Compliance,Adherence, Client,Adherence, Patient,Client Compliances,Compliance, Client,Compliance, Patient,Compliance, Therapeutic,Compliance, Treatment,Cooperation, Patient,Non Adherent Patient,Non-Adherence, Patient,Non-Adherent Patients,Non-Compliance, Patient,Nonadherence, Patient,Noncompliance, Patient,Patient Non Adherence,Patient Non Compliance,Patient, Non-Adherent,Therapeutic Compliances,Treatment Compliances
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D002032 Bulimia Eating an excess amount of food in a short period of time, as seen in the disorder of BULIMIA NERVOSA. It is caused by an abnormal craving for food, or insatiable hunger also known as "ox hunger". Binge Eating,Bulimias,Eating, Binge
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D005473 Fluoxetine The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants. Fluoxetin,Fluoxetine Hydrochloride,Lilly-110140,N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine,Prozac,Sarafem,Lilly 110140,Lilly110140
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Michael J Devlin, and Juli A Goldfein, and Eva Petkova, and Huiping Jiang, and Pamela S Raizman, and Sara Wolk, and Laurel Mayer, and Janel Carino, and Dara Bellace, and Claudia Kamenetz, and Ilyse Dobrow, and B Timothy Walsh
December 2012, Journal of consulting and clinical psychology,
Michael J Devlin, and Juli A Goldfein, and Eva Petkova, and Huiping Jiang, and Pamela S Raizman, and Sara Wolk, and Laurel Mayer, and Janel Carino, and Dara Bellace, and Claudia Kamenetz, and Ilyse Dobrow, and B Timothy Walsh
June 1995, Nihon rinsho. Japanese journal of clinical medicine,
Michael J Devlin, and Juli A Goldfein, and Eva Petkova, and Huiping Jiang, and Pamela S Raizman, and Sara Wolk, and Laurel Mayer, and Janel Carino, and Dara Bellace, and Claudia Kamenetz, and Ilyse Dobrow, and B Timothy Walsh
September 2013, Behaviour research and therapy,
Michael J Devlin, and Juli A Goldfein, and Eva Petkova, and Huiping Jiang, and Pamela S Raizman, and Sara Wolk, and Laurel Mayer, and Janel Carino, and Dara Bellace, and Claudia Kamenetz, and Ilyse Dobrow, and B Timothy Walsh
January 2019, Behavior therapy,
Michael J Devlin, and Juli A Goldfein, and Eva Petkova, and Huiping Jiang, and Pamela S Raizman, and Sara Wolk, and Laurel Mayer, and Janel Carino, and Dara Bellace, and Claudia Kamenetz, and Ilyse Dobrow, and B Timothy Walsh
May 2003, The International journal of eating disorders,
Michael J Devlin, and Juli A Goldfein, and Eva Petkova, and Huiping Jiang, and Pamela S Raizman, and Sara Wolk, and Laurel Mayer, and Janel Carino, and Dara Bellace, and Claudia Kamenetz, and Ilyse Dobrow, and B Timothy Walsh
April 2012, International journal of group psychotherapy,
Michael J Devlin, and Juli A Goldfein, and Eva Petkova, and Huiping Jiang, and Pamela S Raizman, and Sara Wolk, and Laurel Mayer, and Janel Carino, and Dara Bellace, and Claudia Kamenetz, and Ilyse Dobrow, and B Timothy Walsh
January 2001, Eating behaviors,
Michael J Devlin, and Juli A Goldfein, and Eva Petkova, and Huiping Jiang, and Pamela S Raizman, and Sara Wolk, and Laurel Mayer, and Janel Carino, and Dara Bellace, and Claudia Kamenetz, and Ilyse Dobrow, and B Timothy Walsh
February 2005, Biological psychiatry,
Michael J Devlin, and Juli A Goldfein, and Eva Petkova, and Huiping Jiang, and Pamela S Raizman, and Sara Wolk, and Laurel Mayer, and Janel Carino, and Dara Bellace, and Claudia Kamenetz, and Ilyse Dobrow, and B Timothy Walsh
January 2020, Psychotherapy and psychosomatics,
Michael J Devlin, and Juli A Goldfein, and Eva Petkova, and Huiping Jiang, and Pamela S Raizman, and Sara Wolk, and Laurel Mayer, and Janel Carino, and Dara Bellace, and Claudia Kamenetz, and Ilyse Dobrow, and B Timothy Walsh
November 2009, The International journal of eating disorders,
Copied contents to your clipboard!